FDA Approves PIMJETMI With Abbisko Milestone Tied to U.S. Sale
EMD Serono announced on November 10, 2026, that the U.S. Food and Drug Administration had approved PIMJETMI (pimicotinib) for adults with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection may cause worsening functional limitation or severe morbidity. The once-daily oral drug also sets up a new payment for developer Abbisko Therapeutics: an additional milestone upon the first U.S. commercial sale. Abbisko independently developed the small-molecule colony-stimulating…